PlainRecalls
FDA Drug Moderate Class II Terminated

Arformoterol Tartrate Inhalation Solution, 15 mcg/2mL, 2 mL Sterile Unit-Dose Vial packaged in 5 x 2 mL Sterile Unit-Dose Vials per pouch, NDC 69097-168-48; 60 (12 x 5) x 2 mL Sterile Unit-Dose Vials per carton, NDC 69097-168-64, Rx Only, Manufactured by: Cipla Ltd., Indore SEZ, Pithampur, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059.

Reported: October 12, 2022 Initiated: September 29, 2022 #D-1550-2022

Product Description

Arformoterol Tartrate Inhalation Solution, 15 mcg/2mL, 2 mL Sterile Unit-Dose Vial packaged in 5 x 2 mL Sterile Unit-Dose Vials per pouch, NDC 69097-168-48; 60 (12 x 5) x 2 mL Sterile Unit-Dose Vials per carton, NDC 69097-168-64, Rx Only, Manufactured by: Cipla Ltd., Indore SEZ, Pithampur, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059.

Reason for Recall

Lack of Assurance of Sterility: environmental monitoring failure.

Details

Recalling Firm
CIPLA
Units Affected
9041 cartons
Distribution
Product was distributed nationwide to distributors/wholesalers who may have further distributed the product.
Location
Warren, NJ

Frequently Asked Questions

What product was recalled?
Arformoterol Tartrate Inhalation Solution, 15 mcg/2mL, 2 mL Sterile Unit-Dose Vial packaged in 5 x 2 mL Sterile Unit-Dose Vials per pouch, NDC 69097-168-48; 60 (12 x 5) x 2 mL Sterile Unit-Dose Vials per carton, NDC 69097-168-64, Rx Only, Manufactured by: Cipla Ltd., Indore SEZ, Pithampur, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059.. Recalled by CIPLA. Units affected: 9041 cartons.
Why was this product recalled?
Lack of Assurance of Sterility: environmental monitoring failure.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 12, 2022. Severity: Moderate. Recall number: D-1550-2022.